198 related articles for article (PubMed ID: 18194407)
1. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.
Brown B; Diamantopoulos A; Bernier J; Schöffski P; Hieke K; Mantovani L; Launois R; Griebsch I; Robinson P
Value Health; 2008; 11(5):791-9. PubMed ID: 18194407
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis.
Chan AL; Leung HW; Huang SF
Clin Drug Investig; 2011 Oct; 31(10):717-26. PubMed ID: 21744880
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Griffin S; Walker S; Sculpher M; White S; Erhorn S; Brent S; Dyker A; Ferrie L; Gilfillan C; Horsley W; Macfarlane K; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():49-54. PubMed ID: 19567214
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
5. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
6. Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.
van der Linden N; van Gils CW; Pescott CP; Buter J; Vergeer MR; Groot CA
Eur Arch Otorhinolaryngol; 2015 Aug; 272(8):2007-16. PubMed ID: 24943191
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Curran D; Giralt J; Harari PM; Ang KK; Cohen RB; Kies MS; Jassem J; Baselga J; Rowinsky EK; Amellal N; Comte S; Bonner JA
J Clin Oncol; 2007 Jun; 25(16):2191-7. PubMed ID: 17538164
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
Bernier J; Schneider D
Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal antibodies for the treatment of head and neck cancer].
Sautois B; Martin M; Demez P; Piret P; Devillers D; Moreau P
Rev Med Liege; 2009; 64(5-6):284-6. PubMed ID: 19642460
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in the treatment of head and neck cancer.
Bernier J
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1539-52. PubMed ID: 17134359
[TBL] [Abstract][Full Text] [Related]
13. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck.
Levy AR; Johnston KM; Sambrook J; Donato B; Penrod JR; Corral M; Chasen M
Curr Med Res Opin; 2011 Dec; 27(12):2253-9. PubMed ID: 22017232
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
Teoh DC; Rodger S; Say J; Hartley A
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
[No Abstract] [Full Text] [Related]
15. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.
Chan A; Teoh D; Sanghera P; Hartley A
Radiother Oncol; 2009 Dec; 93(3):654. PubMed ID: 19524312
[No Abstract] [Full Text] [Related]
16. Cetuximab in squamous cell carcinoma of the head and neck.
Hitt R; Martín P; Hidalgo M
Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic issues in head and neck oncology.
de Souza JA; de Lima Lopes G; Cohen EE
Curr Opin Oncol; 2013 May; 25(3):213-7. PubMed ID: 23508082
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
Bourhis J; Lefebvre JL; Vermorken JB
Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
[TBL] [Abstract][Full Text] [Related]
19. Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence.
Numico G; Franco P; Cristofano A; Migliaccio F; Spinazzé S; Silvestris N; Cante D; Sciacero P; La Porta MR; Girelli F; Ricardi U
Crit Rev Oncol Hematol; 2013 Feb; 85(2):112-20. PubMed ID: 22743346
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
Annemans L; Van Cutsem E; Humblet Y; Van Laethem JL; Bleiberg H
Acta Clin Belg; 2007; 62(6):419-25. PubMed ID: 18351186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
